From e-cigarettes to buckyball Google Doodle

> E-cigarette story of the week: Michael Felberbaum of the AP files a concise, yet complete story about the pros and cons of e-cigarettes and whether they should be regulated by the FDA as a drug-delivery device. Pro: Yes, they contain carcinogens, but not a significantly relevant amount and they're still better than regular cigarettes; Con: If they claim to be a stop-smoking aid, then they need to go through clinical trials just like any other drug delivery device. Story

> Professor Jean-Christophe Leroux, an expert in galenic studies at the Swiss Federal Institute of Technology in Zurich, has won the Debiopharm Life Sciences Award 2010 sponsored by the Debiopharm Group, a Swiss-based biopharmaceutical group of companies The theme for the award was drug delivery and pharmaceutical technology. "We were seduced by his innovative research, his general expertise and broad overall knowledge in drug delivery," said Rolland-Yves Mauvernay, Debiopharm's president and founder. Debiopharm release 

> You want controlled delivery of nanoparticles? Three words: mesoporous silica nanoparticles. Report 

>  A contact-lens-based drug delivery system for glaucoma treatment is among the 31 new health-related research projects funded by $13 million from Canada's Collaborative Health Research Projects program. More here

> Generex Biotechnology discovers social media. Generex release

Drug delivery patent of the week: Localized drug delivery using drug-loaded nanocapsules Patent

Drug delivery job of the week: Postdoctoral Fellow--Novel Drug Delivery /Oncology, University of Hawaii at Hilo, College of Pharmacy Listing
 
And Finally... For the 25th anniversary of the buckyball, which still holds promise in drug delivery, Google celebrated with a Google Doodle. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.